Immune checkpoint inhibitors: a narrative review of considerations for the anaesthesiologist.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 32007241.
- Also identified by DOI 10.1016/j.bja.2019.11.034 and PMC identifier 7890563.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Immunotherapy has revolutionised the treatment of oncologic malignancies. Immune checkpoint inhibitors represent a new class of immunotherapy drugs. Although these drugs show promise, they are associated with immune-related adverse reactions. An increasing number of patients who undergo surgery will have had treatment with immune checkpoint inhibitors. In this narrative review article, we discuss their mechanism of action, therapeutic effects, pertinent toxicities, and address specific perioperative considerations for patients treated with immune checkpoint inhibitors.
Medical subject headings
- Anesthesiologists
- Antineoplastic Agents, Immunological
- Immunotherapy
- Neoplasms
- Perioperative Care
- Physician's Role